Health Discovery Corporation Announces Issuance of First Patent Covering Prostate Cancer Biomarkers
Published: Sep 28, 2011
SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY) is pleased to announce that the United States Patent and Trademark Office has issued the first of what the Company expects to be several patents covering methods to screen for the presence of prostate cancer using genomic biomarkers that were identified by HDC researchers using the Company's patented RFE-SVM algorithm. The genomic biomarkers covered by the claims of HDC's Patent No. 8,008,012 each performs well individually to distinguish prostate cancer from non-cancer (normal and BPH), however, the unique combination of the genomic biomarkers comprising this HDC prostate cancer test produced an overall test accuracy of 89%. By comparison, the PCA3 test for prostate cancer, developed by Gen-Probe Incorporated and commercially on sale in the United States and Europe, has been reported as having an overall test accuracy of around 81%, while overall test accuracy for PSA is only about 47%.